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The pathophysiology of acute graft-versus-host disease (GVHD) remains poorly understood in humans.
Although T cell subsets have been identiﬁed to play a major role in disease initiation in rodents, clinical data
on the effect of these different subsets are scarce and conﬂicting. To address this question, immunopheno-
typing analyses were performed on the graft in 210 patients. The onset of acute GVHD was retrospectively
correlated with these subpopulations. In an adjusted analysis, only the absolute count of CD45lo/CD62Llo
CD8þ T cells (effector memory T cells) was signiﬁcantly associated with the onset of grade 2 to 4 acute GVHD.
Thus, in contrast to experimental data, we found that the number of effector memory but not of naïve T cells
was associated with the onset of GVHD. These results should be kept in mind while clinical trials, which aim
to deplete naïve T cells, are underway in several institutions.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD), the leading
cause of transplantation-relatedmortality [1,2], still occurs in
40% to 70% of transplantations [3,4]. Donor T cells are major
effectors of both graft-versus-host disease (GVHD) and
graft-versus-leukemia effects [5,6]. During the last decade.
T cells subsets have been investigated to better understand
the chronology of and to predict onset of aGVHD. They aredivided into 4 main subsets: naïve, central memory, effector
memory, and terminally differentiated T cells. Naïve and
central memory T cells strongly expressed CD62L. Naïve and
terminally differentiated T cells expressed CD45RA, whereas
other memory T cells do not. Naïve T cells after activation in
lymphoid organs have been implicated in the genesis of
GVHD in experimental models [7,8]. Conversely, alloreactive
effector memory T cells are immediate effectors [9-11]. In
humans, in vitro studies demonstrated an increased capacity
to induce alloreactivity in naïve CD4 T cells [12,13]. A
prospective and a retrospective study in patients tend to
conﬁrm this hypothesis, showing that naïve CD4 T cells
represent a signiﬁcant biomarker of onset aGVHD [14,15].
Nevertheless, these studies included a small number of
patients. As graft engineering now allows efﬁciently
removing the naïve T cell subset [16], with the aim of
Table 1
Association of aGVHD Grades 2 to 4 with Tertiles of Absolute Counts of T Cell
Subpopulations
T Cell Subpopulation Multivariate Analysis
CIF (95% CI) SHR (95% CI) P Value
CD3þ/4þ/62Lþ/45RAþ .57
.1-15.7 41% (30-53) 1
15.7-50.8 53% (40-64) .66 (.37-1.17)
50.8-228 53% (41-64) .78 (.43-1.40)
CD3þ/4þ/62L/45RA .74
.1-20.7 34% (23-45) 1
20.7-39.1 55% (42-66) .81 (.40-1.64)
39.1-148 59% (46-69) .83 (.38-1.81)
CD3þ/4þ/62Lþ/45RA .45
.1-21.5 36% (25-47) 1
21.5-59 58% (45-68) .82 (.45-1.52)
59-231 54% (42-65) 1.18 (.59-2.37)
CD3þ/8þ/62Lþ/45RAþ .31
0-13.6 43% (31-54) 1
13.6-37 55% (42-66) .82 (.47-1.44)
37-265 50% (38-61) .75 (.43-1.29)
CD3þ/8þ/62L/45RA .024
.05-11.9 34% (23-45) 1
11.9-27.5 45% (33-56) 1.26 (.63-2.52)
27.5-140 69% (56-78) 1.98 (1.00-3.94)
CD3þ/8þ/62Lþ/45RA .42
0-5.94 40% (28-51) 1
5.94-14 52% (39-63) 1.14 (.63-2.03)
14-84.9 56% (43-67) 1.29 (.67-2.48)
CD3þ/8þ/62L/45RAþ .095
0-3.59 33% (22-44) 1
3.59-10.3 50% (38-61) 1.42 (.76-2.63)
10.3-139 65% (52-75) 1.88 (.89-3.98)
CIF indicates cumulative incidence function; 95% CI, 95% conﬁdence
interval; SHR, subdistribution hazard ratio.
Results are cumulative incidence at 100 days and subdistribution hazard
ratio with their 95% conﬁdence intervals. Multivariate analyses are adjusted
on recipient age, donor type, donor age, gender matching, cytomegalovirus
matching, stem cell source, conditioning intensity (myeloablative or
reduced intensity) and total body irradiation 12 Gy and ATG. After
multivariate analysis, only the absolute count of CD8þ TEM is signiﬁcantly
associated with onset of grade 2 to 4 GVHD.
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to assess the impact of the different T cell subsets on GVHD
onset in a large cohort of patients.
PATIENTS AND METHODS
We analyzed the grafts content in a cohort of 210 patients who
underwent allogeneic stem cell transplantation from bone marrow (BM) or
granulocyte colonyestimulating factor (GCSF)emobilized peripheral blood
between January 2009 and June 2012. These 210 patients were part of 402
consecutive patients who underwent transplantation in the same period in
our institution. Indeed, during the period of the study, immunophenotyping
of the grafts depended on several material constraints, such as availability of
technicians capable of the typing and of ﬂuorochromes; therefore,
this typing was completed for 210 grafts. Nevertheless, we performed an
analysis to demonstrate that there was no selection bias (Supplementary
Table 1). Cord blood transplantations were excluded. Main characteristics
of analyzed patients were collected retrospectively from the ProMISe
(Project Manager Internet Server) database, which is the central data
management system used by the European group of Blood and Marrow
Transplantation. They are summarized in Supplementary Table 1. The main
outcome was occurrence of aGVHD grade 2 to 4. aGVHD was graded
according to the score described by Glucksberg et al. [17]. The ethics
committee of the Saint Louis Hospital approved the study.
We collected 1 milliliter of fresh BM or GCSF-mobilized graft to perform
immunophenotyping. To be representative of the graft composition, when
there was a graft manipulation (deserythrocytation for BM grafts) before
administration, the sample was collected after the manipulation.
After each graft collection, samples were stained using the multitest
kit (Becton Dickinson, Le Pont de Claix, France) CD45RAFITC/CD62LPE/
CD3PerCP/CD4APC and CD45RAFITC/CD62LPE/CD3PerCP/CD8APC. Then, a4-color ﬂow cytometry was performed. For CD3þ/CD4þ and CD3þ/CD8þ
lymphocytes, central memory T (TCM) cells were deﬁned as CD45RA/
CD62Lhigh, effector memory (TEM) as CD45RA/CD62Llo, and terminally
differentiated (TTD) as CD45RAþ/CD62Llo, whereas naïve T cells were
CD45RAþ/CD62Lhigh. Results were expressed as absolute counts and as
percentage of total lymphocytes. Cells were acquired on a FACS Scan ﬂow
cytometry analyzer (FACs Calibur, Becton Dickinson) and analyzed using
CellQuestPro software (Becton Dickinson).
Statistics
Characteristics of patients investigated for T cells subsets were
compared using Wilcoxon rank-sum tests and Fisher’s exact tests. Time to
aGVHD 2 to 4 was counted from the date of transplantation to the date of
aGVHD or date of last follow-up. The cumulative incidence of aGVHD was
estimated using usual methods and compared according to tertiles of
T lymphocytes subpopulations using Gray’s test. Adjusted analyses were
performed using Fine- Gray proportional subdistribution hazards models.
Parameters used for adjusted analysis are listed in Table 1. All tests were
2 sided and P values <.05 were considered as indicating signiﬁcant
association. Analyses were performed using R statistical software version
2.15.2.
RESULTS
Characteristics of include patients and other patients who
underwent transplantation during the same period (not
included) are compared in Supplementary Table 1. There was
a slight male predominance. Median recipient age was
46 years (range, 4 to 66). Most patients were treated for
hematological malignancies and 36 hematopoietic stem cell
transplantations were performed for hemoglobinopathies or
BM failure. Identical sibling transplantations were performed
in 115 patients, matched unrelated donor transplantations in
68, and mismatched unrelated donor transplantations in 23.
There was a gender mismatch for 90 patients. Main stem cell
source was GCSF-mobilized peripheral blood stem cells
(PBSC) (78%), whereas BM was used in 46 patients (22%).
Acute myeloblastic leukemia and acute lymphoblastic
leukemia were the main underlying diseases. Forty-six
patients received a myeloablative conditioning regimen
and 129 patients received reduced-intensity conditioning.
Among patients who received a myeloablative conditioning,
26 received a regimen including total body irradiation at a
total dose of 12 Gy. GVHD prophylaxis based on cyclosporine
at the dose of 3 mg/kg i.v. for 98% of the patients combined
with either methotrexate (15 mg/m2 day 1, 10 mg/m2 days 3,
6, and 11) for patients receiving myeloablative conditioning,
or mycophenolate mofetil (2 g/day per os) for patients
receiving reduced-intensity conditioning. Antithymoglobu-
lin (ATG) was added in case of unrelated transplantation.
Total dose of ATG depended on indication ranging from
20 mg/kg for hemoglobinopathies to 5 mg/kg. Median
follow-up from transplantation was 18 months (range, 1 to
39). Median onset of aGVHD was 22 days (range, 5 to 197).
The cumulative incidence of aGVHD 2 to 4 was 52% (95%
conﬁdence interval, 45% to 59%) overall and 49% (95% con-
ﬁdence interval, 42% to 56%) at 100 days. Median number of
naïve, TCM, TEM, for CD4þ T cells were respectively 34.1106/
kg (range, 8.5 to 64.2), 41.1 (range, 12.8 to 68.8), and 29.0
(range, 13.6 to 49.5) and were 24.8  106/kg (range, 10.6 to
45), 8.6 (range, 3.8 to 17.1), 19.6 (range, 8.8 to 32.5), and 6.2
(range, 2.6 to 16.4) respectively for naïve, TCM, TEM, and TTD
CD8þ (Supplementary Table 2).
Unadjusted and adjusted association between tertiles of
absolute counts of T cell subpopulations and onset of aGVHD
are given in Table 1. In a multivariate analysis, only a higher
absolute count of CD3þ/CD8þ/CD45 RA/CD62Lo T cells that
correspond to TEM was associated with the onset of aGVHD
grade 2 to 4 (adjusted hazard ratio, 1.26 and 1.98; P ¼ .02)
Figure 1. Cumulative Incidence curves of aGVHD grade 2 to 4 (top row) and grade 3 to 4 (bottom row) according to tertiles of the absolute count of CD8þ TEM cells in
all grafts (left panels) and in GCSF-mobilized PBSC (right panels).
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and grade 3 to 4 for patients receiving PBSC grafts are
provided in Figure 1. Cumulative incidence curves of aGVHD
grade 2 to 4 and grade 3 to 4 for patients receiving BM grafts
are provided in Supplementary Figure 1.
Because absolute counts of T cell subpopulations were
clearly imbalanced between recipients of PBSC and BM grafts
(Figure 2), data were also analyzed as percent of total
nucleated cells. When using percentages, repartition of the
lymphocytes subsets is better balanced (Figure 3). Using
percentages, there was no signiﬁcant association for any T
cell subsets in univariate and multivariate analysis between
tertiles of percent of T cell subpopulations and onset of
aGVHD (Supplementary Table 3).
DISCUSSION
We analyzed the relationship between T cell subsets
count in BM and GCSF-mobilized PBSC grafts in a large
retrospective cohort. In a multivariate analysis, only a high
absolute count of CD8þ TEM was signiﬁcantly associated with
an increased cumulative incidence of grade 2 to 4 aGVHD.
Previous experimental studies in rodents showed that
donor-derived central memory CD8þ T cells were able to
initiate and maintain aGVHD. Indeed, Zhang et al. showed
that CD44loCD62Lhi CD8þmemory T cells could promote and
sustain aGVHD in a mouse model. They also demonstrated
that CD8þ T cells were primed early by host dendritic cells
[6,18]. Other studies reported that removing CD8þ allo-
reactive T cells in experimental models signiﬁcantly reduced
both the severity and duration of tissue damage [19-21].Conversely, experimental studies on CD4þ T cells showed
that memory T cells cannot generate aGVHD [7,8], whereas
naïve CD4þ T cells initiate and maintain aGVHD [8].
In humans, Yakoub-Agha et al. conducted a prospective
study on the impact of T cell subsets in grafts on GVHD. T cell
proportions were determined using ﬂow cytometry with
antibodies to CD62L, CD45RA, and CCR7. The incidence of
aGVHD was the same as in our study. In this study, CD4þ
naïve T cells was the only subset signiﬁcantly associated with
an increased rate of aGVHD [14]. Chang et al. reported similar
results in a prospective study including 31 patients receiving
stem cell transplantation for hematological malignancies. In
multivariate analysis, the number of naïve CD45RAþ/CD62Lþ
CD4þ T cells was signiﬁcantly associated with a higher risk
of aGVHD. Other subsets did not inﬂuence onset of this
complication [15]. In our study, in a large cohort therewas no
impact of this subset in acute GVHD in adjusted analysis.
Several factors may explain these differences. First, there
was a small number of patients in these 2 previous studies.
Second, in 1 study, patients receiving ATG were excluded.
ATG may delay reconstitution of the CD4þ T cells, whereas
CD8þ subsets recover faster [22]. BM was the main stem cell
source in the study of Yakoub Agha et al., whereas in our
study, it only represents 22% of all grafts. In both studies,
absolute counts of T cells were clearly imbalanced between
BM and PBSC, whereas percentages were similar.
Recently, Waller et al. reported the results of the
immunotyping of 161 bonemarrowand 147 peripheral blood
grafts from the BMTCTN 0201 study [23]. In this study, the
numbers of plasmacytoid dendritic cells and naïve T cells in
Figure 2. Distribution of naive T and B cell subpopulations as absolute counts of lymphocytes according to stem cell source. PB denotes peripheral blood and BM
bone marrow. Box and whisker plots display the median, 25th, and 75th percentile of the distribution (box), and whiskers extend to the most extreme data points.
Absolute counts of T and B cells are higher in peripheral blood for all T cell subpopulations.
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Figure 3. Distribution of naive T and B cell subpopulations as percent of total nucleated cells according to stem cell source. PB denotes peripheral blood and BM bone
marrow. Box and whisker plots display the median, 25th, and 75th percentile of the distribution (box), and whiskers extend to the most extreme data points.
According the relative percentages, T and B cells subsets are more similar comparing bone marrow and peripheral blood except for CD4 T cells.
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survival in multivariable analyses, including recipient and
donor characteristics, such as human leukocyte antigen
mismatch, age, and use of ATG. Conversely, analysis of PB
grafts did not identify a donor cell subset signiﬁcantly
associated with overall survival, relapse, or GVHD. It is, thus,
impossible to compare directly our results with those of
Waller et al. because we have too few BM grafts recipient
who developed grade 3 to 4 aGVHD. In accordance with
Waller et al., we found no impact of naïve T cells in the PB
grafts on incidence of aGVHD. Concerning BM grafts and,
probably because of a lower number, we did not ﬁnd an
effect of naïve T cells.
One limitation of our study is that we did not analyze
regulatory T cell subsets in the grafts, although this subset
might play a major role in prevention and control of aGVHD
[20,24,25]. Furthermore, numbers and not function were
evaluated (as expected from a study performed in human
beings).
Depleting naïve T cells using CD45RA may deplete naïve
regulatory T cell [16], while sparing alloreactive CD8þ T cells
associated with aGVHD in this study. Moving to naïve T cell
depletion into the clinic might, thus, be considered with
caution.
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